المؤلفون: Xu M; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, China., Lu Z; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, China., Wu Z; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, China., Gui M; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, China., Liu G; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, China., Tang Y; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, China., Li W; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai200237, China.

المصدر: Molecular pharmaceutics [Mol Pharm] 2023 Jan 02; Vol. 20 (1), pp. 194-205. Date of Electronic Publication: 2022 Dec 02.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP3A*/metabolism , Enzyme Inhibitors*/pharmacology, Humans ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Drug Interactions ; Computer Simulation

المؤلفون: Lee S; Department of Biological Sciences, KAIST, Daejeon, South Korea., Park BB; College of Pharmacy, Korea University, Sejong, South Korea., Kwon H; College of Pharmacy, Korea University, Sejong, South Korea., Kim V; Department of Biological Sciences, Konkuk University, Seoul, South Korea., Jeon JS; College of Pharmacy, Chungnam National University, Daejeon, South Korea., Lee R; Department of Biological Sciences, Konkuk University, Seoul, South Korea., Subedi M; College of Pharmacy, Korea University, Sejong, South Korea., Lim T; College of Pharmacy, Korea University, Sejong, South Korea., Ha H; College of Pharmacy, Korea University, Sejong, South Korea., An D; Department of Biological Sciences, KAIST, Daejeon, South Korea., Kim J; Department of Biological Sciences, KAIST, Daejeon, South Korea., Kim D; Department of Biological Sciences, Konkuk University, Seoul, South Korea., Kim SK; College of Pharmacy, Chungnam National University, Daejeon, South Korea., Kim S; Department of Biological Sciences, KAIST, Daejeon, South Korea.; KAIST Institute for the BioCentury, KAIST, Daejeon, South Korea., Byun Y; Department of Biological Sciences, KAIST, Daejeon, South Korea.; Biomedical Research Center, Korea University Guro Hospital, Seoul, South Korea.

المصدر: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 269-279.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP3A/*metabolism , Enzyme Inhibitors/*pharmacology , Phosphotransferases (Phosphate Group Acceptor)/*antagonists & inhibitors, Dose-Response Relationship, Drug ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Humans ; Molecular Structure ; Phosphotransferases (Phosphate Group Acceptor)/metabolism ; Structure-Activity Relationship

المؤلفون: Urgaonkar S; Athenex Inc., Conventus Building, Buffalo, New York 14203, United States., Nosol K; Institute of Molecular Biology and Biophysics, ETH Zürich, Otto-Stern-Weg 5, 8093 Zürich, Switzerland., Said AM; Athenex Inc., Conventus Building, Buffalo, New York 14203, United States., Nasief NN; Athenex Inc., Conventus Building, Buffalo, New York 14203, United States., Bu Y; Athenex Inc., Conventus Building, Buffalo, New York 14203, United States., Locher KP; Institute of Molecular Biology and Biophysics, ETH Zürich, Otto-Stern-Weg 5, 8093 Zürich, Switzerland., Lau JYN; Athenex Inc., Conventus Building, Buffalo, New York 14203, United States., Smolinski MP; Athenex Inc., Conventus Building, Buffalo, New York 14203, United States.

المصدر: Journal of medicinal chemistry [J Med Chem] 2022 Jan 13; Vol. 65 (1), pp. 191-216. Date of Electronic Publication: 2021 Dec 20.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Drug Design* , Drug Discovery*, ATP Binding Cassette Transporter, Subfamily B, Member 1/*antagonists & inhibitors , Cryoelectron Microscopy/*methods , Cytochrome P-450 CYP3A/*chemistry , Cytochrome P-450 CYP3A Inhibitors/*pharmacology , Enzyme Inhibitors/*pharmacology, Administration, Oral ; Animals ; Antineoplastic Agents/administration & dosage ; Cytochrome P-450 CYP3A Inhibitors/chemistry ; Docetaxel/administration & dosage ; Enzyme Inhibitors/chemistry ; Humans ; Mice

المؤلفون: Gonzalez E; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Jain S; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Shah P; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Torimoto-Katori N; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Zakharov A; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Nguyễn ÐT; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Sakamuru S; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Huang R; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Xia M; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Obach RS; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Hop CECA; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Simeonov A; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.)., Xu X; Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Rockville, Maryland (E.G., S.J., P.S., N.T.-K., A.Z., D.-T.N., S.S., R.H., M.X. A.S., X.X.); Discovery Technology Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama-shi, Japan (N.T.-K.); Pfizer Inc. Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer, Groton, Connecticut (R.S.O.); and Genentech Inc. Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., San Francisco, California (C.E.C.A.H.) xin.xu3@nih.gov.

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2021 Sep; Vol. 49 (9), pp. 822-832. Date of Electronic Publication: 2021 Jun 28.

نوع المنشور: Journal Article; Research Support, N.I.H., Intramural

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Enzyme Inhibitors*/chemistry , Enzyme Inhibitors*/pharmacokinetics, Cytochrome P-450 CYP2C9/*metabolism , Cytochrome P-450 CYP2D6/*metabolism , Cytochrome P-450 CYP3A/*metabolism , Drug Development/*methods, Biocatalysis ; Drug Discovery/methods ; Drug Interactions ; Humans ; Inactivation, Metabolic ; Metabolic Clearance Rate ; Quantitative Structure-Activity Relationship

المؤلفون: Xiao L; College of Pharmacy, Jinan University.; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University., Bei Y; Biopharmaceutical R&D Center of Jinan University., Li J; Biopharmaceutical R&D Center of Jinan University., Chen M; Biopharmaceutical R&D Center of Jinan University., Zhang Y; Biopharmaceutical R&D Center of Jinan University., Xiang Q; College of Pharmacy, Jinan University.; Institute of Biomedicine and Guangdong Provincial Key Laboratory of Bioengineering Medicine, Jinan University.; Biopharmaceutical R&D Center of Jinan University.

المصدر: Chemical & pharmaceutical bulletin [Chem Pharm Bull (Tokyo)] 2021 Jan 01; Vol. 69 (1), pp. 52-58. Date of Electronic Publication: 2020 Oct 20.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Pharmaceutical Society of Japan Country of Publication: Japan NLM ID: 0377775 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1347-5223 (Electronic) Linking ISSN: 00092363 NLM ISO Abbreviation: Chem Pharm Bull (Tokyo) Subsets: MEDLINE

مواضيع طبية MeSH: 17-Hydroxysteroid Dehydrogenases/*antagonists & inhibitors , Curcumin/*pharmacology , Cytochrome P-450 CYP3A/*metabolism , Enzyme Inhibitors/*pharmacology, 17-Hydroxysteroid Dehydrogenases/metabolism ; Animals ; Curcumin/administration & dosage ; Curcumin/chemistry ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/administration & dosage ; Enzyme Inhibitors/chemistry ; Humans ; Male ; Mice ; Mice, Inbred Strains ; Microsomes, Liver/chemistry ; Microsomes, Liver/metabolism ; Rats ; Rats, Sprague-Dawley ; Tissue Distribution

المؤلفون: Davis MA; Department of Biochemistry and Molecular Biology , University of Arkansas for Medical Sciences , Little Rock , Arkansas 72205 , United States., Barnette DA; Department of Biochemistry and Molecular Biology , University of Arkansas for Medical Sciences , Little Rock , Arkansas 72205 , United States., Flynn NR; Department of Pathology and Immunology , Washington University , St. Louis , Missouri 63130 , United States., Pidugu AS; Department of Neuroscience and Behavioral Biology , Emory University , Atlanta , Georgia 30322 , United States., Swamidass SJ; Department of Pathology and Immunology , Washington University , St. Louis , Missouri 63130 , United States., Boysen G; Department of Environmental and Occupational Health , University of Arkansas for Medical Sciences , Little Rock , Arkansas 72205 , United States., Miller GP; Department of Biochemistry and Molecular Biology , University of Arkansas for Medical Sciences , Little Rock , Arkansas 72205 , United States.

المصدر: Chemical research in toxicology [Chem Res Toxicol] 2019 Jun 17; Vol. 32 (6), pp. 1151-1164. Date of Electronic Publication: 2019 Apr 10.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 8807448 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5010 (Electronic) Linking ISSN: 0893228X NLM ISO Abbreviation: Chem Res Toxicol Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP2C19/*metabolism , Cytochrome P-450 CYP3A/*metabolism , Enzyme Inhibitors/*pharmacology , Terbinafine/*pharmacology, Biocatalysis ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/metabolism ; Humans ; Kinetics ; Models, Molecular ; Molecular Structure ; Terbinafine/chemistry ; Terbinafine/metabolism

المؤلفون: Dong JQ; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Gosset JR; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Fahmi OA; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Lin Z; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Chabot JR; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Terra SG; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Le V; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Chidsey K; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Nouri P; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Kim A; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Buckbinder L; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut., Kalgutkar AS; Clinical Pharmacology (J.Q.D.), Pharmacokinetics, Pharmacodynamics, and Metabolism (J.R.G., J.R.C., A.S.K.), Statistics (V.L.), Early Clinical Development (K.C., A.K.), and Cardiovascular and Metabolic Disease Research Unit (L.B.), Pfizer Inc., Cambridge, Massachusetts; and Pharmacokinetics, Pharmacodynamics, and Metabolism (O.A.F., Z.L.), Clinical Development (S.G.T.), and Clinical Assay Group (P.N.), Pfizer Inc., Groton, Connecticut amit.kalgutkar@pfizer.com.

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2017 May; Vol. 45 (5), pp. 501-511. Date of Electronic Publication: 2017 Mar 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Acetamides/*pharmacology , Cytochrome P-450 CYP3A/*biosynthesis , Enzyme Inhibitors/*pharmacology , Pyrimidinones/*pharmacology, Acetamides/pharmacokinetics ; Adult ; Cells, Cultured ; Cytochrome P-450 CYP3A/genetics ; Cytochrome P-450 CYP3A/metabolism ; Enzyme Induction/drug effects ; Enzyme Inhibitors/pharmacokinetics ; Female ; Hepatocytes/drug effects ; Hepatocytes/enzymology ; Humans ; Male ; Middle Aged ; Peroxidase/antagonists & inhibitors ; Pyrimidinones/pharmacokinetics ; RNA, Messenger/biosynthesis ; RNA, Messenger/genetics ; Young Adult

المؤلفون: Zak M; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA. Electronic address: mzak@gene.com., Liederer BM; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Sampath D; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Yuen PW; Pharmaron Beijing Co. Ltd, 6 Taihe Road, BDA, Beijing 100176, PR China., Bair KW; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Baumeister T; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Buckmelter AJ; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Clodfelter KH; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Cheng E; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Crocker L; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Fu B; Pharmaron Beijing Co. Ltd, 6 Taihe Road, BDA, Beijing 100176, PR China., Han B; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Li G; Pharmaron Beijing Co. Ltd, 6 Taihe Road, BDA, Beijing 100176, PR China., Ho YC; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Lin J; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Liu X; Pharmaron Beijing Co. Ltd, 6 Taihe Road, BDA, Beijing 100176, PR China., Ly J; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., O'Brien T; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Reynolds DJ; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Skelton N; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Smith CC; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Tay S; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Wang W; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Wang Z; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Xiao Y; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Zhang L; Pharmaron Beijing Co. Ltd, 6 Taihe Road, BDA, Beijing 100176, PR China., Zhao G; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA., Zheng X; Forma Therapeutics Inc., 500 Arsenal Street, Watertown, MA 02472, USA., Dragovich PS; Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

المصدر: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2015 Feb 01; Vol. 25 (3), pp. 529-41. Date of Electronic Publication: 2014 Dec 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3405 (Electronic) Linking ISSN: 0960894X NLM ISO Abbreviation: Bioorg Med Chem Lett Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP3A/*chemistry , Enzyme Inhibitors/*chemistry , Nicotinamide Phosphoribosyltransferase/*antagonists & inhibitors, Animals ; Binding Sites ; Cell Line, Tumor ; Cell Membrane Permeability/drug effects ; Cell Proliferation/drug effects ; Crystallography, X-Ray ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/chemistry ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics ; Cytochrome P-450 CYP3A Inhibitors/toxicity ; Dogs ; Enzyme Inhibitors/pharmacokinetics ; Enzyme Inhibitors/therapeutic use ; Female ; Half-Life ; Humans ; Kinetics ; Madin Darby Canine Kidney Cells ; Mice ; Mice, Nude ; Molecular Dynamics Simulation ; Neoplasms/drug therapy ; Neoplasms/pathology ; Nicotinamide Phosphoribosyltransferase/metabolism ; Protein Binding ; Protein Structure, Tertiary ; Pyrimidines/chemistry ; Pyrimidines/therapeutic use ; Pyrimidines/toxicity ; Solubility ; Structure-Activity Relationship ; Thermodynamics ; Transplantation, Heterologous ; Water/chemistry

المؤلفون: Fuchs I; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany., Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G

المصدر: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2013 Mar; Vol. 69 (3), pp. 507-13. Date of Electronic Publication: 2012 Sep 12.

نوع المنشور: Comparative Study; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP3A Inhibitors* , Hypericum*, Cytochrome P-450 CYP3A/*biosynthesis , Enzyme Inhibitors/*administration & dosage , Ketoconazole/*administration & dosage , Plant Extracts/*administration & dosage , Receptors, Steroid/*drug effects, Adult ; Area Under Curve ; Biotransformation ; Cross-Over Studies ; Cytochrome P-450 CYP3A/genetics ; Drug Administration Schedule ; Drug Interactions ; Enzyme Induction ; Germany ; Humans ; Hydroxylation ; Male ; Metabolic Clearance Rate ; Midazolam/administration & dosage ; Midazolam/analogs & derivatives ; Midazolam/pharmacokinetics ; Middle Aged ; Plants, Medicinal ; Pregnane X Receptor ; Receptors, Steroid/metabolism ; Substrate Specificity ; Transcription, Genetic/drug effects ; Young Adult

المؤلفون: Akiyoshi T; Keio University Faculty of Pharmacy, Tokyo, Japan., Saito T, Murase S, Miyazaki M, Murayama N, Yamazaki H, Guengerich FP, Nakamura K, Yamamoto K, Ohtani H

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2011 Apr; Vol. 39 (4), pp. 724-8. Date of Electronic Publication: 2011 Jan 06.

نوع المنشور: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Cytochrome P-450 CYP3A Inhibitors*, 14-alpha Demethylase Inhibitors/*metabolism , Cimetidine/*pharmacology , Cytochrome P-450 CYP3A/*genetics , Enzyme Inhibitors/*pharmacology , Itraconazole/*pharmacology, 14-alpha Demethylase Inhibitors/chemistry ; Androgens/chemistry ; Androgens/metabolism ; Cimetidine/metabolism ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/metabolism ; Genetic Variation ; Heme/metabolism ; Humans ; Hydroxytestosterones/metabolism ; Itraconazole/metabolism ; Recombinant Proteins/antagonists & inhibitors ; Recombinant Proteins/metabolism ; Testosterone/metabolism